This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
MG America has announced a strategic alliance with Romaco North America to cross-promote and sell complementary production machinery in North America. The agreement synergizes machinery offerings from the two pharma industry equipment companies, allowing each to offer a more comprehensive range of market-proven solutions to their respective customer bases, as well as enhanced equipment servicing options.
The alliance will largely focus on complementary solutions. For instance, MG America will now be offering its customers several packaging platforms from Romaco, including cartoners, such as the Promatic P 91 intermittent motion and Promatic PC 4200 continuous motion models. MG America also will be showcasing Romaco’s Kilian series of tablet presses, along with a variety of coating and granulation equipment.
Romaco will highlight MG America’s full line of capsule filling machinery, including the recently introduced Essentia compact unit suitable for medium- to large-batch manufacturing. Romaco also will be able to sell a range of MG America packaging equipment, including case packers, tray formers, sachet machines, and palletizers.
“Teaming up with our friends at Romaco provides an immediate, turnkey array of solutions that align with and supplement our own equipment portfolio,” says Claudio Radossi, president of MG America. “Synergistic relationships are designed to make all parties stronger, and this agreement certainly accomplishes that—not only for Romaco and MG America but for our growing, evolving customer bases.”
Sabri Demirel, managing director for Romaco North America, agrees. “Combining our strengths allows each company not only to expand its portfolio with proven, highly regarded solutions, but also grow the resources we have in the sales and servicing field. This alliance takes two companies with decades in the market and strong name recognition and makes them even more attractive to pharma manufacturers and other customers.”
